Published Population Pharmacokinetic Models of Imatinib Perform Poorly on TDM Data from Pediatric Patients
Targeted Oncology · 2025
DOI: 10.1007/s11523-025-01172-2 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Targeted Oncology, 2025. Verfasst von Tianwu Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Imatinib Mesylate, Models, Biological, Antineoplastic Agents, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Børnecancerfonden, Director Michael Hermann Nielsen's Memorial Foundation, Arvid Nilssons Fond.
Abstract (Originalsprache)
BACKGROUND: Population pharmacokinetic models can potentially provide suggestions for an initial dose and the magnitude of dose adjustment during therapeutic drug monitoring procedures of imatinib. Several population pharmacokinetic models for imatinib have been developed over the last two decades. However, their predictive performance is still unknown when extrapolated to different populations, especially children. OBJECTIVE: This study aimed to evaluate the predictive performance of these published models on an external real-world dataset containing data from both adults and children. METHODS: A real-world dataset was collected, containing observations from adult and pediatric patients with Philadelphia chromosome-positive/Philadelphia chromosome-like acute lymphoblastic leukemia and chronic myeloid leukemia (N = 39) treated with imatinib. A systematic review through PubMed was conducted to identify qualified population-pharmacokinetic models for external evaluation (i.e., prediction-based, simulation-based, and Bayesian forecasting diagnostics). Standard allometric scaling was used for models that were developed based on data from adults only. RESULTS: Fifteen published models were found for evaluation, of which only two were based on data from both children and adults. Prediction-based diagnostics showed that some models had an acceptable level of bias. The model by Shriyan et al. (with allometric scaling) performed best with a median prediction error of 1.24%. However, no models performed well on precision even when allometric scaling was used, where the lowest median absolute prediction error was 37.66% using the model by Schmidli et al. The models by Golabchifar et al. and Schmidli et al. (both with allometric scaling) performed the best of all tested models, with a median prediction error ≤ 15%, median absolute prediction error ≤ 40%, fraction of prediction error within ± 20% (F20) ≥ 0.3, and within ± 30% (F30) nearly 0.4. Simulation-based diagnostics showed that most of the observations outside the 90% prediction interval were from children. Bayesian forecasting showed that the model prediction could be improved using one prior sample, particularly in adults. CONCLUSIONS: Current models fail to accurately predict imatinib plasma concentrations in our real-world dataset, especially for children. Future pharmacokinetic studies should focus on developing better models for pediatric populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
- Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Childhood Cancer Unit, Karolinska University Hospital, and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
- Department of Haematology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
- TamCAM Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere University Hospital, Tampere, Finland.
Förderung
- Børnecancerfonden
- Director Michael Hermann Nielsen's Memorial Foundation
- Arvid Nilssons Fond
- Director Michael Hermann Nielsen’s Memorial Foundation
- Engineer Otto Christensen's Foundation
- Manufacturer Einar Willumsen’s Memorial Foundation
- Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
- Copenhagen University
Zitieren
APA
Yang, T., Rasmussen, A. S. B., Weimann, A., Thastrup, M., Rank, C. U., Als-Nielsen, B., Malmros, J., Wik, H. S., Lohi, O., Overgaard, U., Johannsdottir, I. M. R., Vaitkeviciene, G., Dalhoff, K., Schmiegelow, K., & Lund, T. M. (2025). Published Population Pharmacokinetic Models of Imatinib Perform Poorly on TDM Data from Pediatric Patients. Targeted Oncology. https://doi.org/10.1007/s11523-025-01172-2
Vancouver
Yang T, Rasmussen ASB, Weimann A, Thastrup M, Rank CU, Als-Nielsen B, et al. Published Population Pharmacokinetic Models of Imatinib Perform Poorly on TDM Data from Pediatric Patients. Targeted Oncology. 2025. doi:10.1007/s11523-025-01172-2
BibTeX
@article{Yang2025,
author = {Yang, Tianwu and Rasmussen, Anna Sofie Buhl and Weimann, Allan and Thastrup, Maria and Rank, Cecilie Utke and Als-Nielsen, Bodil and Malmros, Johan and Wik, Hilde Skuterud and Lohi, Olli and Overgaard, Ulrik and Johannsdottir, Inga Maria Rinvoll and Vaitkeviciene, Goda and Dalhoff, Kim and Schmiegelow, Kjeld and Lund, Trine Meldgaard},
title = {Published Population Pharmacokinetic Models of Imatinib Perform Poorly on TDM Data from Pediatric Patients},
journal = {Targeted Oncology},
year = {2025},
doi = {10.1007/s11523-025-01172-2}
}
EUVIMED